Potential Breakthrough For Early Developments Of Alzheimer's Disease

The U.S. Food and Drug Administration (FDA) Advisory Committee unanimous finding that Donanemab (Eli Lilly) is effective for the treatment of early Alzheimer’s Disease.

If approval is granted by the FDA, donanemab will be the second traditional approval of an Alzheimer’s treatment that changes the underlying course of the disease, and the third FDA approval overall in this class of treatments.

The Alzheimer’s Association and members of the Association’s Early Stage Advisory Group each submitted comments urging the Advisory Committee to recommend traditional approval of donanemab. The next regu...